Scarica l'app Stockscreener
12.34
6.83%
0.85
Precedente Chiudi:
$11.49
Aprire:
$11.27
Volume 24 ore:
112.00K
Relative Volume:
0.42
Capitalizzazione di mercato:
$155.31M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+12.72%
1M Prestazione:
-13.62%
6M Prestazione:
-76.69%
1 anno Prestazione:
-59.74%
Intervallo 1D:
$11.27
$13.09
Intervallo di 1 settimana:
$10.46
$13.09
Portata 52W:
$6.875
$74.49
Neurogene Inc Stock (NGNE) Company Profile
Nome
Neurogene Inc
Settore
Industria
Telefono
(877) 237-5020
Indirizzo
535 W 24TH STREET, NEW YORK
Confronta NGNE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NGNE
Neurogene Inc
|
12.39 | 155.31M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.75 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.78 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
594.54 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
230.40 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
228.75 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Neurogene Inc Stock (NGNE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-06-27 | Iniziato | BMO Capital Markets | Outperform |
| 2024-06-11 | Iniziato | Robert W. Baird | Outperform |
| 2024-04-29 | Iniziato | Leerink Partners | Outperform |
| 2024-03-21 | Iniziato | William Blair | Outperform |
| 2024-01-08 | Iniziato | H.C. Wainwright | Buy |
| 2024-01-05 | Iniziato | Stifel | Buy |
| 2024-01-04 | Iniziato | TD Cowen | Outperform |
Mostra tutto
Neurogene Inc Borsa (NGNE) Ultime notizie
Wellington Management Group LLP Grows Stock Holdings in Neurogene Inc. (NASDAQ:NGNE) - The AM Reporter
BMO cuts Neurogene stock target to $16 from $45, keeps Outperform By Investing.com - Investing.com South Africa
Wellington Management Group LLP Increases Stock Holdings in Neurogene Inc. (NASDAQ:NGNE) - Defense World
JPMorgan Chase & Co. Purchases 476,418 Shares of Neurogene Inc. (NASDAQ:NGNE) - Defense World
Neurogene (NASDAQ:NGNE) Given New $16.00 Price Target at BMO Capital Markets - Defense World
Neurogene Inc. Amends Agreement, Issues Warrants By Investing.com - Investing.com South Africa
Neurogene Inc. Amends Agreement, Issues Warrants - Investing.com
Neurogene Amends Agreement With Baker Bros To Increase Nomination Threshold - marketscreener.com
BMO cuts Neurogene stock target to $16 from $45, keeps Outperform - Investing.com Canada
NGNE stock touches 52-week low at $8.35 amid market challenges - Investing.com Australia
NGNE stock touches 52-week low at $8.35 amid market challenges By Investing.com - Investing.com South Africa
Neurogene Announces Peer-Reviewed Publication Demonstrating Gene Therapy Candidate NGN-401 with EXACT™ Technology Regulates Transgene Expression in Preclinical Models of Rett Syndrome - BioSpace
Neurogene reports progress in gene therapy regulation technology By Investing.com - Investing.com Canada
Neurogene reports progress in gene therapy regulation technology - Investing.com
Bronstein, Gewirtz & Grossman, LLC Encourages Neurogene Inc. (NGNE) Investors to Inquire about Securities Investigation - ACCESS Newswire
Q1 Earnings Estimate for Neurogene Issued By HC Wainwright - The AM Reporter
What is Leerink Partnrs’ Forecast for Neurogene Q1 Earnings? - Defense World
Neurogene Inc. (NASDAQ:NGNE) Receives $59.80 Average PT from Brokerages - Defense World
What is William Blair’s Forecast for Neurogene Q1 Earnings? - Defense World
What is HC Wainwright’s Estimate for Neurogene Q1 Earnings? - Defense World
Neurogene Reports 2024 Financial Results and Advances in Rett Syndrome Trial - MSN
PNC Financial Services Group Inc. Makes New $71,000 Investment in Neurogene Inc. (NASDAQ:NGNE) - Defense World
Analyzing Neurogene (NASDAQ:NGNE) & Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Neurogene (NASDAQ:NGNE) Receives Outperform Rating from William Blair - Defense World
Stifel maintains Buy on Neurogene stock with $46 target By Investing.com - Investing.com UK
Neurogene (NASDAQ:NGNE) Given New $50.00 Price Target at HC Wainwright - Defense World
Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates - BioSpace
Neurogene Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Neurogene Inc. (NGNE) reports earnings - Quartz
Neurogene Inc Files For Mixed Shelf Offering Of Up To $300 MillionSEC Filing -March 24, 2025 at 04:38 pm EDT - MarketScreener
Neurogene Inc (NASDAQ: NGNE): Overvalued Compared To Others? - Stocks Register
Insiders Re-Evaluate Their US$1.46m Stock Purchase As Neurogene Falls To US$251m - simplywall.st
NEUROGENE Earnings Preview: Recent $NGNE Insider Trading, Hedge Fund Activity, and More - Nasdaq
Rhumbline Advisers Buys 1,326 Shares of Neurogene Inc. (NASDAQ:NGNE) - Defense World
Neurogene: Potential To Target Root Cause Of Rett Syndrome With NGN-401 - Seeking Alpha
Neurogene (NASDAQ:NGNE) Shares Down 8.4% – Here’s Why - Defense World
Neoleukin Therapeutics, Inc. Announces Reduction in the Workforce -March 08, 2023 at 05:00 pm EST - marketscreener.com
Neurogene to Participate in Upcoming Conferences - Business Wire
Can These 3 Healthcare Conferences Reveal Neurogene's Next Big Move? - Stock Titan
Neurogene Insiders Placed Bullish Bets Worth US$1.46m - Yahoo Canada Finance
Neurogene (NGNE) to Release Quarterly Earnings on Monday - Defense World
Neurogene (NGNE) Projected to Post Quarterly Earnings on Monday - MarketBeat
Neurogene Inc (NGNE) Shares Decline Despite Market Challenges - The News Heater
Bronstein, Gewirtz & Grossman, LLC Is Investigating Neurogene Inc. (NGNE) And Encourages Stockholders to Connect - accessnewswire.com
Should You Expect Neurogene Inc (NASDAQ:NGNE) To Recover From Its 38.11% Gain From Highs? - Marketing Sentinel
Get in on Neurogene Inc’s (NGNE) buy-in window today! - SETE News
Neurogene Inc [NASDAQ: NGNE] Sees Increase in Stock Value - Knox Daily
Rett Syndrome Market Growth Projections 2024-2034: - openPR
Neurogene Inc (NGNE) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Neurogene Inc Azioni (NGNE) Dati Finanziari
Non sono disponibili dati finanziari per Neurogene Inc (NGNE). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Neurogene Inc Azioni (NGNE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Samsara BioCapital GP, LLC | 10% Owner |
Nov 26 '24 |
Buy |
25.83 |
48,770 |
1,259,623 |
1,717,127 |
| Cvijic Christine Mikail | President and CFO |
Nov 22 '24 |
Buy |
20.48 |
24,000 |
491,400 |
76,844 |
| McMinn Rachel | Chief Executive Officer |
Nov 22 '24 |
Buy |
20.40 |
47,500 |
969,000 |
1,297,859 |
0.77%
0.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):